T
he 2017 American College of Cardiology (ACC)/ American Heart Association (AHA) blood pressure (BP) guideline recommended initiation of antihypertensive medication based on a combination of cardiovascular disease (CVD) risk and average BP level, and lowered BP treatment goals. 1 It has been estimated that the application of the 2017 ACC/AHA BP guidelines would result in a recommendation for antihypertensive drug therapy in approximately 4.2 million additional US adults and would increase the number of adults with treated hypertension who have a BP above the recommended target of <130/80 mm Hg by about 7.9 million adults compared to the 2003 Seventh Joint National Committee Report (JNC7) guideline. 1, 2 Intensive BP treatment to a systolic BP goal of 120 or 130 mm Hg results in a larger reduction in CVD risk compared with treatment to 140 or 150 mm Hg. [3] [4] [5] For the same lowering of BP, absolute risk reduction is greater in patients with higher CVD risk. 6 Thus, the 2017 ACC/AHA BP guideline recommendation of antihypertensive drug treatment based on a combination of BP levels and high CVD risk may be more efficient than prior recommendations in US BP guidelines. The risk-stratified approach may yield greater absolute CVD risk reduction for the same number of adults treated compared to what would be expected when treatment is based on BP levels only. 7 However, high CVD risk patients might also be at increased risk for antihypertensive treatment-related serious adverse events (SAEs). We estimated the potential population health impact, including benefits and harms, associated with achieving and maintaining 2017 ACC/AHA guidelinerecommended BP goals in US adults aged ≥45 years with hypertension compared with maintaining current BP levels, achieving BP goals recommended in the 2003 JNC7 guideline, or achieving 2014 Eighth Joint National Committee panel member (JNC8PM) report BP goals. 1, 8, 9 The current analysis complements our previous estimates of the population-recommended treatment initiation or intensification under the 2017 ACC/ AHA BP guideline by projecting the potential number of CVD events that could be prevented if the 2017 ACC/AHA BP guideline-recommended BP goals were achieved and maintained. 2 We compared these estimates with the number of CVD events expected with maintenance of current BP levels or with achievement of BP goals set by the 2 previous national guidelines. 8, 9 
METHODS
The data, analytic methods, and study materials will not be made publicly available to other researchers for purposes of reproducing the results or replicating the procedure. However, with review and approval, the information is available from the REGARDS study (REasons for Geographic and Racial Differences in Stroke) under established data sharing procedures. The NHANES (National Health and Nutrition Examination Surveys) are a publicly available data source.
We defined mutually exclusive hypertension treatment groups based on recommendations in the 2017 ACC/AHA, JNC7, and JNC8PM guidelines using data on current antihypertensive medication use status, current BP level, age, and comorbidities (Tables I, II , and III in the online-only Data Supplement). For this simulation study, we estimated 2 inputs described in detail below: (1) 10-year CVD event rates in hypertension treatment groups, and (2) US adult population sizes for each group. Expected CVD risk reduction with BP lowering to goal was based on response to treatment to current and recommended BP levels in a meta-analysis of antihypertensive drug treatment randomized trials ( Figure 1 ). 3 Expected risk of treatment-related SAEs with BP lowering was based on treatment-related harms observed in patients treated to standard (ie, treatment goal of systolic BP [SBP] <140 mm Hg) and intensive BP goals (ie, treatment goal of SBP <120 mm Hg) using pooled data from SPRINT (Systolic Blood Pressure Intervention Trial) and the ACCORD-BP trial (Action to Control Cardiovascular Risk in Diabetes Blood Pressure).
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CVD Event Rates: The REGARDS Study
The REGARDS study enrolled 30 239 black and white women and men age ≥45 years from all 48 contiguous US states and the District of Columbia between January 2003 and October 2007. We excluded participants missing baseline BP measurements (n=143), information on self-reported antihypertensive medication use (n=225), or variables needed to
Clinical Perspective
What Is New?
• The 2017 American College of Cardiology/American Heart Association Blood Pressure Guideline recommended lower blood pressure thresholds for antihypertensive medication initiation and intensification for most patients with hypertension.
• We projected the potential population health impact of implementing the 2017 guideline among US adults age ≥45 years with hypertension compared with current blood pressure levels and with prior guidelines.
• Achieving and maintaining 2017 guideline goals over 10 years could prevent 3.0 million cardiovascular disease events-a greater number of events prevented compared with prior guidelines-but could also lead to 3.3 million more treatmentrelated serious adverse events.
What Are the Clinical Implications?
• Achieving and maintaining 2017 American College of Cardiology/American Heart Association blood pressure goals could prevent a greater number of cardiovascular disease events than achieving prior US guideline goals but could also lead to more serious adverse events. 
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determine hypertension treatment group according to the 2017 ACC/AHA, JNC7, and JNC8PM guidelines (n=195). 1, 8, 9 After excluding an additional 458 participants who lacked follow-up data, 29 218 participants were available for inclusion in our analyses ( Figure I in the online-only Data Supplement). REGARDS participants were followed from baseline through the occurrence of a CVD event, death, loss-to-follow-up, or December 31, 2014, whichever occurred first. CVD events included stroke (fatal and nonfatal), coronary heart disease (fatal and nonfatal myocardial infarction or coronary heart disease death), or heart failure hospitalization (fatal or nonfatal). Event adjudication procedures have been described and are provided in the supplement (Table IV in the onlineonly Data Supplement) . [12] [13] [14] [15] [16] We chose the REGARDS study as the sole source for BP-related CVD event rates because it is one of the largest, most contemporary population-based samples of US adults with rigorously adjudicated CVD events. Additionally, the CVD event rates in the REGARDS study are likely to be more generalizable than those obtained in randomized trials.
Hypertension Treatment Group Population Sizes: NHANES
To attain sufficient sample size, we pooled NHANES surveys conducted between 2011 and 2014. Due to the REGARDS study age range, the NHANES analysis was restricted to participants ≥45 years of age. We included NHANES participants with 3 systolic and diastolic BP measurements obtained during the study visit (n=5728). Participants missing data on variables needed to determine hypertension treatment group according to the 2017 ACC/AHA, JNC7, and JNC8PM guidelines were excluded (n=335). 1, 8, 9 After these exclusions, data from 5393 participants were available for analysis ( Figure II in the online-only Data Supplement).
BP Measurements in REGARDS and NHANES
For REGARDS study participants, BP was measured 2 times in the seated position, after 5 minutes of rest, and at least 30 seconds apart by a trained health professional during in-home examinations using an aneroid sphygmomanometer and an appropriately sized cuff. The mean of the 2 measurements defined REGARDS participants' BP. For NHANES participants, BP was measured 3 times in the seated position, after 5 minutes of rest, 30 seconds apart, and by a trained physician using a mercury sphygmomanometer with an appropriately sized cuff. The mean of the 3 measurements defined BP in NHANES.
Benefits and Risks of BP Lowering
We estimated CVD risk reduction associated with achieving recommended versus current systolic BP levels using the hazard ratios estimated in a network meta-analysis of 42 randomized BP-lowering trials including 144 220 participants (Table V in the online-only Data Supplement). 3 Treatment benefits for the population with isolated diastolic hypertension or with higher diastolic BP hypertension stage than systolic BP stage were analyzed in sensitivity analyses that categorized adults into hypertension treatment groups based on the higher hypertension stage, considering both diastolic or systolic BP (Table VI in the online-only Data Supplement). We estimated risks for antihypertensive treatment-related SAEs using a weighted average of SAE risks observed in the SPRINT and ACCORD-BP (Table VII in the online-only Data Supplement).
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Statistical Analysis
We calculated characteristics of REGARDS and NHANES 2011 to 2014 study participants overall and among those (Tables I and II in  the online-only Data Supplement) . 17 Because the REGARDS study only enrolled black and white participants and oversampled blacks, we weighted the REGARDS study cohort to match the US adult population sizes by age, sex, and black/ nonblack race groups. Specifically, statistical weights were calculated for population subgroups defined by age, sex, and race by dividing the percentage of US adults (estimated from NHANES) over the percentage of REGARDS study participants that belong to each subgroup. Analyses incorporated sampling weights using STATA V14 (Stata Corp, College Station, TX). The 95% confidence intervals for the 10-year risk of CVD events were calculated as described by Fine and Gray. 17 The 95% CIs of each NHANES hypertension treatment group were calculated using Taylor-series variance estimation. 18 Analyses incorporated sampling weights using STATA V14.
We multiplied the observed REGARDS 10-year CVD event rates upper and lower bounds 95% CIs by hypertension treatment group size to project the number of CVD events expected over the next 10 years if current BP levels were to be sustained. Next, we multiplied this expected number of CVD events by the hazard ratio corresponding to current systolic BP and guideline-specific recommended BP goals (Table  IV in the online-only Data Supplement) to project population benefit: the number of CVD events prevented by achieving and maintaining the 2017 ACC/AHA or JNC7 guideline or JNC8PM BP goals for 10 years. Treatment efficiency was calculated by dividing the projected number of events prevented by the number of adults treated, multiplied by 1000. To quantify uncertainty, analysis-of-extremes sensitivity analyses were performed in which the number of CVD events prevented and treatment efficiency was recalculated using the upper and lower 95% confidence bounds of both treatment effect size and REGARDS 10-year CVD event rates. [19] [20] [21] For population health benefit and treatment efficiency estimates, uncertainty ranges (URs) represent the lower and upper bounds from the analysis-of-extremes sensitivity analysis.
To project population health harms (ie, number of treatment-related SAEs) expected over 10 years, associated with initiation or intensification of antihypertensive medication needed to achieve and maintain guideline-recommended BP goals compared with maintaining current BP levels, we multiplied the pooled 10-year risk of treatment-related SAEs in the standard treatment arms of SPRINT and ACCORD-BP (ie, those treated to SBP <140 mm Hg) to hypertension treatment groups when the guideline-recommended BP goals were <140 or 150 mm Hg (Table VII in the online-only Data Supplement). 10, 11 For hypertension treatment groups with guideline-recommended BP goals of <130 mm Hg, we multiplied the pooled intensive treatment arm SAE risk by the population sizes. Definitions of treatment-related SAEs in SPRINT and ACCORD-BP are provided in Table X in the online-only Data Supplement. SAEs included hypotension, syncope, bradycardia, electrolyte abnormalities, injurious falls, and acute kidney injury among others (Table X in the online-only Data Supplement).
Subgroup and Sensitivity Analyses
For subgroup analyses, NHANES-based hypertension treatment group size and REGARDS baseline CVD event rate estimates were generated for subgroups defined by sex, race/ ethnicity (ie, white, non-Hispanic black, Hispanic), age (<65 and ≥65 years), chronic kidney disease status defined by a self-report of being on dialysis, eGFR <60 mL/(min·1.73 m 2 ) or albumin to creatinine ratio of ≥30 mg/g, diabetes mellitus status, clinical CVD status, and age ≥65 years with "robust" health status (based on walking speed, prior falls, and mobility status; see pages 5-6 of the online-only Data Supplement). Because lower BP targets may be difficult to achieve in clinical practice settings, we repeated all the analyses assuming that only 75% of the treatment groups recommended a SBP goal of <130 mm Hg would reach this goal, which reflects adherence rates observed in BP-lowering clinical trials, 22 compared to 100% reaching the SBP goals of <140 or <150 mm Hg.
Main effectiveness estimates reflect incomplete medication adherence in the trials included in the network metaanalysis. The lower bounds of our uncertainty ranges imply an effect size reflecting medication adherence as low as 27% (Table XI in the online-only Data Supplement). 22 Data management was conducted using SAS version 9.4 (SAS Institute, Cary, NC) and data analysis using Stata V14 and Microsoft Excel. The REGARDS study and NHANES were approved by the Institutional Review Boards governing research in human subjects, and all participants provided written informed consent.
RESULTS
A total of 17.9, 14.4, and 9.6 million US adults age ≥45 years are recommended antihypertensive medication initiation by the 2017 ACC/AHA BP guideline, the JNC7, and the JNC8PM, respectively. In addition, a total of 24.0, 18.8, and 11.4 million currently treated US adults age ≥45 years are recommended antihypertensive medication intensification by the 2017 ACC/AHA BP guideline, the JNC7, and the JNC8PM, respectively.
Compared with maintaining current BP levels, achieving the 2017 ACC/AHA guideline-recommended BP goals in US adults with hypertension could prevent 3.0 million CVD events over 10 years of treatment (UR, 1.1-5.1) (Figure 2 ). Of these CVD events prevented, 83% resulted from treatment in adults with a current BP ≥140/90 mm Hg; 35% of all CVD events prevented would be in those initiating antihypertensive treatment and 65% in those intensifying current antihypertensive treatment. Achieving 2017 ACC/AHA guideline BP goals would likely prevent 0.5 million (UR, 0.2-0.7) and 1.4 million (UR, 0.7-2.0) more CVD events compared to achieving the JNC7-or JNC8PM-recommended BP goals, respectively (Tables 1 and 2 ). Achieving 2017 ACC/AHA guideline BP goals could also lead to an increase in treatment-related SAEs: 3.3 million (UR, 2.2-4.4) more SAEs compared with maintaining current BP levels, and 1.2 million (UR, 0.8-1.6) and 2.4 million (UR, ORIGINAL RESEARCH ARTICLE 1.7-3.2) and more compared to achieving the JNC7-or JNC8PM-recommended BP goals (Figures 3 and 4 ; Table  XII and XIII in the online-only Data Supplement). Achieving and maintaining the 2017 ACC/AHA guideline goals for 10 years could prevent 71.9 CVD events per 1000 treated (UR, 26.6-122.3) compared to maintaining current BP levels ( Figure 2 ). Compared to achieving JNC7 BP goals, achieving the 2017 guideline BP goals would be more efficient in patients with a current BP ≥140/90 mm Hg and without diabetes mellitus or chronic kidney disease (Figure 3 ). Achieving the 2017 guideline BP goals would be more efficient compared to achieving JNC8PM goals in all patients (Figure 4) . Overall, treatment would also be more efficient in those intensifying current treatment compared with those initiating treatment.
Achieving the 2017 ACC/AHA guideline-recommended BP goals could prevent more CVD events than achieving JNC8PM goals in every subgroup or achieving JNC7 goals in every subgroup with the exception of people with diabetes mellitus and chronic kidney disease (ie, groups in which BP treatment targets are identical in the JNC7 and 2017 guidelines) ( Table 3 ).
Sensitivity Analyses
Results were similar when high diastolic BP was incorporated into assigning BP lowering effects (Table XIV 
DISCUSSION
Implementing, achieving, and maintaining the 2017 ACC/AHA guideline-recommended BP goals would likely prevent about 3.0 million CVD events over 10 years compared with maintaining current BP levels in US adults age ≥45 years with hypertension. This represents a larger population health impact than would be expected by achieving BP goals recommended in the JNC7 or JNC8PM guidelines. All population subgroups would benefit by achieving the 2017 guideline goals. The majority (83%) of the CVD events that would be prevented by achieving 2017 guideline goals would accrue in patients with a current BP ≥140/90 mm Hg, a level of BP for which treatment with antihypertensive drug therapy has been recommended for more than 25 years. 8, 27, 28 The current analysis suggests that achieving and maintaining 2017 ACC/AHA BP guideline goals would be efficient, preventing 71.9 CVD events per 1000 treated adults over 10 years compared with maintaining current BP levels. Treatment was also efficient among those recommended drug treatment initiation or intensification. This finding is important because some investigators have voiced concern that the 2017 BP guideline overextended the reach of hypertension di- Circulation. [29] [30] [31] [32] The lower BP thresholds used to define hypertension indeed lead to more diagnoses. 33 However, because the recommendation for antihypertensive drug treatment in patients with pretreatment BP 130 to 139/80 to 89 mm Hg was limited to those at high CVD risk, treatment under the 2017 guideline would lead to more health gains while only extending treatment to 5.4% more adults with hypertension compared to JNC7. 2 Based on the 2017 guideline recommendations, adults with stage 1 hypertension for whom initiation of pharmacological antihypertensive treatment is recommended have a The uncertainty range represents the upper and lower bounds from the analysis of extremes sensitivity analysis where the number of cardiovascular disease events prevented is recalculated using the upper and lower confidence bounds of both treatment effect size magnitude in the trials meta-analysis 3 and REGARDS (REasons for Geographic and Racial Differences in Stroke) 10-year cardiovascular event rate. [19] [20] [21] The lower bound is calculated using the upper bound of the hazard ratio and the lower bound of the REGARDS 10-year cardiovascular event rate. The upper bound is calculated using the lower bound of the hazard ratio and the upper bound of the REGARDS 10-year cardiovascular event rate.
ACC indicates American College of Cardiology; AHA, American Heart Association; CKD, chronic kidney disease; CVD, cardiovascular disease; DBP, diastolic blood pressure; JNC7, Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; SBP, systolic blood pressure; and UR, uncertainty range.
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6-fold higher rate of CVD events compared with their counterparts who have also have stage 1 hypertension, but are too low-risk to qualify for antihypertensive drug therapy. 34 The range of treatment efficiency we estimated among 2017 guideline treatment groups can be used by hypertension control programs to prioritize highest treatment efficiency groups for resource allocation and early guideline implementation. We demonstrated in prior publications that treating hypertension is either cost-effective or cost-saving in most adults and, despite higher initial treatment costs and the potential for SAEs, more intensive SBP treatment is cost-effective over a lifetime compared to standard treatment in high CVD risk individuals. 35, 36 The results of the current analysis are consistent with a prior modeling study by Bundy et al 37 projecting that achieving and maintaining 2017 ACC/AHA guidelinerecommended BP goals would prevent twice as many CVD events than achieving and maintaining JNC8PM goals among US adults age ≥40 years. Similar to that analysis, we used a network meta-analysis of 42 randomized BP-lowering trials including 144,220 participants as the source of CVD risk reductions associated with achieving recommended versus current systolic BP levels. 3 However, in their analysis, Bundy et al based treatment group sizes on NHANES 2013 to 2016 and CVD event rates on older cohort studies (ie, the ARIC study [ [1985] [1986] [1987] [1988] [1989] [1990] [1991] [1992] [1993] [1994] [1995] [1996] [1997] [1998] [1999] [2000] [2001] [2002] [2003] [2004] and calibrated the CVD event rates to match rates reported in the AHA 2015 Heart Disease and Stroke Statistics. These input decisions resulted in uniformly higher baseline event rates than were entered into our models. We choose to use the REGARDS study as our source for CVD events rates as REGARDS represents one of the largest, most contemporary population- A and B show the number of cardiovascular disease events prevented per 1000 individuals treated with achieving guideline-recommended blood pressure goals compared to current blood pressure levels for the 2017 ACC/AHA and the JNC7 guidelines within guideline-recommended treatment groups among those currently taking and not taking antihypertensive medication. C and D show the number of treatment-related SAEs expected with achieving guideline-recommended blood pressure goals compared to current blood pressure levels for the 2017 ACC/AHA and the JNC7 guidelines within guideline-recommended treatment groups among those currently taking and not taking antihypertensive medication. The subgroups presented represent different treatment target recommendations in the different guidelines. CVD events included stroke (fatal and nonfatal), coronary heart disease (fatal and nonfatal myocardial infarction or coronary heart disease death), or heart failure (fatal or nonfatal). ACC indicates American College of Cardiology; AHA, American Heart Association; CKD, chronic kidney disease; CVD, cardiovascular disease, DM, diabetes mellitus, JNC7, Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; SAE, serious adverse event; and SBP, systolic blood pressure. *A hypertension treatment group in which antihypertensive medication initiation of intensification is not recommended. †Treated uncontrolled groups where antihypertensive medication intensification is recommended. Because of lack of clinicaltrial based evidence on incremental SAE risk in these groups, we assumed an additional SAE risk midway between the SAE risk with intensification to an intensive goal (<130/80 mm Hg) and that of intensification to a <140/90 mm Hg goal in treatment-naive patients.
Circulation. ORIGINAL RESEARCH ARTICLE based samples of US adults with rigorously adjudicated CVD events with 10 years of follow-up. Accurate CVD incidence rates are difficult to determine at a national population level.
Even though the population health benefits could be substantial, and treatment efficiency would be acceptable, the expected benefits of achieving the 2017 ACC/AHA guideline BP goals must be weighed against the potential harms of pharmacological treatment. We estimated that achieving and maintaining the 2017 guideline goals could cause the same number of SAEs as the number of CVD events prevented (about 3 million over 10 years). However, CVD events and SAEs are generally not equivalent in severity and should not be directly compared. A proportion of CVD events are fatal or nonfatal but severely disabling, whereas the overwhelming majority of SAEs (eg, syncope, hypotension, and electrolyte abnormalities) are nonfatal, and the acute kidney injury follow-up experience in SPRINT suggest, many SAEs are mild transient events from which participants make a complete recovery within 12 months. 38 Evidence regarding the harms of antihypertensive treatment, especially intensive therapy, is more limited than evidence of benefit. Until recently, reporting on harms in many BP-lowering trials has not been rigorous or standardized. The treatment-related SAE rates used in our analysis were from contemporary trials in high CVD risk patients that are among the A and B show the number of cardiovascular disease events prevented per 1000 individuals treated with achieving guideline-recommended blood pressure goals compared to current blood pressure levels for the 2017 ACC/AHA and the JNC8PM guidelines within guideline-recommended treatment groups among those currently taking and not taking antihypertensive medication. The subgroups presented represent different treatment target recommendations in the different guidelines. CVD events included stroke (fatal and nonfatal), coronary heart disease (fatal and nonfatal myocardial infarction or coronary heart disease death), or heart failure (fatal or nonfatal). ACC indicates American College of Cardiology; AHA, American Heart Association; CKD, chronic kidney disease; CVD, cardiovascular disease; DM, diabetes mellitus; JNC8PM, Eighth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; SAE, serious adverse event; and SBP, systolic blood pressure. *A hypertension treatment group in which antihypertensive medication initiation of intensification is not recommended. †Treated uncontrolled groups where antihypertensive medication intensification is recommended. Because of lack of clinical trial-based evidence on incremental SAE risk in these groups, we assumed an additional SAE risk midway between the SAE risk with intensification to an intensive goal (<130/80 mm Hg) and that of intensification to a <140/90 mm Hg goal in treatment-naive patients.
few that carefully recorded and ascertained SAEs. 10, 11 The favorable balance between benefits and harms observed in HYVET (Hypertension in the Very Elderly Trial), SHEP (Systolic Hypertension in the Elderly Program), and the SPRINT elderly participants support the 2017 ACC/AHA guideline recommendation of the same BP treatment goals in most ambulatory older persons and all other adults. [39] [40] [41] However, the 2017 Recommendation for intensification of antihypertensive medication by the 2017 ACC/AHA high blood pressure guideline but not by JNC8PM guideline includes SBP 130 to <140 mm Hg and those with SBP 140 to <150 mm Hg aged ≥ 60 years without diabetes or CKD. The UR represents the upper and lower bounds from the analysis of extremes sensitivity analysis where the number of cardiovascular disease events prevented is recalculated using the upper and lower confidence bounds of both treatment effect size magnitude in the trials meta-analysis 3 and REGARDS 10-year cardiovascular event rate. [19] [20] [21] The lower bound is calculated using the upper bound of the hazard ratio and the lower bound of the REGARDS 10-year cardiovascular event rate. The upper bound is calculated using the lower bound of the hazard ratio and the upper bound of the REGARDS 10-year cardiovascular event rate. ACC indicates American College of Cardiology; AHA, American Heart Association, CKD, chronic kidney disease; CVD, cardiovascular disease; DBP; diastolic blood pressure; JNC7, Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; JNC8PM, Eighth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; REGARDS, REasons for Geographic and Racial Differences in Stroke study; SBP, systolic blood pressure; and UR, uncertainty range. ORIGINAL RESEARCH ARTICLE ACC/AHA guideline recommended that healthcare providers exercise caution when initiating or intensifying treatment in older adults. Until SAE risk prediction tools are implemented in clinical practice, "clinical judgment" will be the recommended approach to assess the potential for antihypertensive medication SAE risk in individual patients. Achieving and maintaining the hypertension treatment and BP control goals recommended in the 2017 ACC/AHA BP guideline and simulated in our analysis will be challenging, but systematic, multicomponent interventions can improve hypertension control dramatically. 42 Integrated health systems, such as Kaiser Permanente of Northern California and the Veterans Health Administration, have achieved control rates of >80% to 90% for systolic/diastolic BP targets goals of <140/90 mm Hg. 43, 44 A recent meta-analysis of 121 randomized trials of practice-based interventions to improve BP control found that multilevel, multicomponent strategies involving team-based care with antihypertensive medication titration by nurses or pharmacists resulted in a large systolic BP reduction (mean, -7.1 mm Hg over a median of 6 months). 42 Adoption of the 2017 guideline treatment goals should be pursued on a platform of high-quality in-and out-of-office BP measurement. 1 This report draws on several major strengths. Effectiveness estimates for BP lowering were obtained from a recent network meta-analysis of 42 BP-lowering trials involving 144 200 participants. 3 Findings in the network meta-analysis were consistent whether or not SPRINT results were included. 3 Because our goal was to generate estimates that are generalizable to the US adult population, we used NHANES, a nationally representative survey of the US adult population, and REGARDS, the most contemporary populationbased sample of US adults with rigorously adjudicated CVD events. The current analysis also has important limitations. Although the REGARDS study enrolled US adults from the 48 contiguous US states, blacks and residents from the Southeastern US are overrepresented by design. Therefore, the CVD event rates may be higher in the REGARDS study compared with the general US population. However, we reweighted the REGARDS population to match age, sex, and race distribution in NHANES. Another limitation is that we did not account for future changes in blood pressure, antihypertensive medication use, or other covariates. 
However, our analysis used the absolute 10-year CVD event rates from REGARDS and hazard ratios derived from intention-to-treat analyses of clinical trials, both of which incorporate time-varying changes in antihypertensive medications, blood pressure levels, and other characteristics over time. Therefore, had we adjusted for these time-varying changes in our analysis, we might have overestimated the number of CVD events prevented. The current analysis was limited to adults ≥45 years of age. We assumed no heterogeneity of treatment effect in terms of relative risk reduction across subgroups. About 51% of US adults with hypertension currently have controlled BP using the 140/90 mm Hg goal (70 to 90% control in treated patients), so 100% implementation of the 2017 ACC/AHA guideline is unlikely in the short term and represents a "best-case" scenario. [43] [44] [45] [46] Both NHANES and REGARDS based their BP estimates on averages at a single visit in contrast to the ≥2 measurements over ≥2 occasions recommended in the 2017 ACC/ AHA and JNC7 guidelines. REGARDS is not directly representative of the US adult population and has the potential to over-or underestimate CVD risk. We assumed that higher risk of specific treatment-related SAEs in the intensive compared with standard blood pressure treatment arm in SPRINT and ACCORD-BP were valid representations of intensive antihypertensive drug treatment SAE risk in community-dwelling patients. However, this likely represents a conservative estimate as there was no overall difference in SAEs between the intensive and standard treatment arms in SPRINT and, due to the unblinded nature of the study, the potential for bias in ascertainment of SAEs is a serious concern (ie, favoring more SAE reporting in the intensive arm).
In conclusion, the results from this analysis suggest that achieving and maintaining the 2017 ACC/AHA guideline-recommended BP goals could prevent about 3 million CVD events over 10 years when compared to current BP levels, but implementing the 2017 guideline could also lead to about 3 million more treatmentrelated SAEs.
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